Aceso Life Science Group Ltd. has provided a quarterly update outlining significant progress in addressing its financial stability and going concern issues. According to the announcement, most of the Group's outstanding bank loans and corporate note payables as of 31 March 2025 have either been re-financed or extended for three years, with an option for a one-year further extension, or settled through the realization of listed equity investments. The company also successfully re-financed its UK Loan, entering into a new facility agreement on 16 September 2025, securing approximately GBP87.3 million from various lenders to replace the prior facility. These actions, along with ongoing measures such as obtaining new sources of financing, seeking support from the ultimate controlling shareholder, extending repayment terms, and pledging or realizing unsecured assets, have resolved the issues that previously led to a Disclaimer of Opinion in the company's annual report. The board believes that these steps have addressed the company's liquidity and financial concerns, signaling improved stability for shareholders and potential investors.